A Phase 4 interventional study of Bupivicaine intervention arm and Placebo arm in Complex Obstetric Surgery, Perioperative Pain Management and Cesarean Delivery, sponsored by University of Tennessee. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of Tennessee · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 306th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 49 that started in 2025, is one of 359 in phase 4, reaches primary completion later than 203 of the 236 other live ones, and was the 1,082nd registered.
5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 156 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 49 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,099 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 475 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 1,181 have an industry lead sponsor. The 10 most frequent:
University of Tennessee is the lead sponsor of 142 studies on the registry; 21 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
University of Tennessee has 8 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
98 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,181 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).
The Transversus Abdominis Plane (TAP) block is a regional anesthesia technique that targets the nerves innervating the abdominal wall, providing effective postoperative analgesia for patients undergoing various abdominal surgeries, including cesarean deliveries. The standard clinical practice for TAP blocks typically involves local anesthetics like bupivacaine, which, when administered in the appropriate plane, has been shown to reduce opioid consumption and improve pain management in the postoperative period.
Transversus abdominal plane (TAP) blocks, when administered intraoperatively, have demonstrated significant benefits in managing postoperative pain, especially in abdominal surgeries. Placing the TAP block during surgery provides early and prolonged analgesia, potentially reducing the need for postoperative opioids and improving recovery outcomes. A study completed in 2007 was one of the first to highlight the effectiveness of intraoperative TAP block placement in patients undergoing lower abdominal surgeries, showing a significant reduction in opioid consumption and better pain control. In the context of cesarean section, an intraoperative TAP block was shown to provide effective analgesia with a reduction in postoperative narcotic use. Similarly, a randomized trial in 2017 demonstrated that intraoperative TAP blocks significantly improved pain scores and reduced opioid consumption in patients undergoing colorectal surgeries. Furthermore, a study completed in 2014 found that performing TAP blocks intraoperatively for laparoscopic cholecystectomy patients resulted in lower visual analog scale (VAS) pain scores in the recovery room and reduced the incidence of postoperative nausea and vomiting. These findings underscore the advantages of intraoperative TAP block placement in enhancing postoperative analgesia across a variety of abdominal procedures.
Despite the widespread use of TAP blocks, there remains a gap in the literature regarding the effectiveness of bupivacaine TAP block use placed intraoperatively during more complex obstetric surgeries. Most existing studies focus on the use of TAP blocks for pain management after routine Pfannenstiel cesarean deliveries, with limited attention given to their role in cases involving higher-risk or more complicated obstetric situations, such as cesareans with significant intra-abdominal adhesions or other complications.
Although bupivacaine is commonly used in TAP blocks, its specific efficacy, optimal dosing, and potential benefits when placed intraoperatively in complex obstetric cases remain underexplored. The limited data in this area presents a critical gap in our understanding of how best to optimize pain management and improve surgical outcomes for women undergoing cesarean delivery, particularly in high-risk obstetric cases.
This blinded randomized controlled trial (RCT) seeks to address this gap by evaluating the effectiveness of intraoperative TAP blocks with bupivacaine during complex cesarean sections, focusing on the impact on postoperative analgesia and pain scores. By clarifying the role of bupivacaine in TAP blocks during complex obstetric surgery, this study aims to contribute valuable insights to the field of obstetric anesthesia and improve the perioperative experience for patients undergoing cesarean delivery.
Primary Objective: To assess the effect of intraoperative transversus abdominis plane (TAP) blocks on the amount of opioid pain medications expressed as morphine milliequivalents (MME) used postoperatively in patients who have undergone cesarean delivery (CD) in the setting of complex obstetric surgery (COS).
Primary Endpoint/Outcome: Pain medication requested, expressed as MMEs, from 0-24 and 0-48 hours after surgery.
Secondary Endpoint(s)/Outcome(s):
Total MME at 1-week after surgery Functional assessment of activities of daily life (ADL) at 1-week post operatively Number of unplanned postoperative visits within 6-months of surgery Geographic region of patients needing complex obstetric surgery.
Hypothesis: The investigators hypothesize that utilization of the TAP block will reduce MME requirements by 20% for patients who have undergone CD in the setting of COS.
5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
This study's planned enrollment of 120 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →University of Tennessee is the lead sponsor of 142 studies on the registry; 21 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has a history of a least one of the following:
Exclusion Criteria:
Placebo group TAP (Transversus Abdominis Plane) block syringe will include 30mL normal saline.
Drug: Placebo arm
TAP (Transversus Abdominis Plane) blocks will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine.
Drug: Bupivicaine intervention arm
TAP blocks in intervention group will include 0.5% bupivacaine in 30mL solution of 15mL normal saline and 15mL bupivacaine
Placebo group TAP block syringe will include 30mL normal saline
Pain medication requested
Total pain medication requested expressed in morphine milligram equivalents.
Time frame: Between 0-24 and 0-48 hours after surgery
Total MME at one week after surgery
Time frame: One week postoperatively
Functional assessment of activities of daily life (ADL) at one week postoperatively
Time frame: One week postoperatively
Number of unplanned postoperative visits within six months of surgery
Time frame: Six months postoperatively
Geographic region of patients needing complex obstetric surgery
Heat maps to evaluate the distribution of patients across different demographic categories based on race and age within certain zip codes
Time frame: 24 months - through the duration of the study
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 34 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.